Clinical evaluation of endothelial cell decrease with VisThesia(sodium hyaluronate 1.5%, lidocaine1%) in phacoemulsification surgery

Clinical evaluation of endothelial cell decreases with VisThesia in phacoemulsification surgery.

Article specifications

This Randomized, Multicentral clinical trial was published in 2005 in journal of cataract and refractive surgery (IF 2015:3.02) by Spanish and Italian ophthalmologists.

In this study the efficacy and safety of VisThesia (sodium hyaluronate 1.5%, lidocaine1%) as an ophthalmic viscosurgical device (OVD) in phacoemulsification were evaluated.

50 patients in 2 different hospital in Spain and Italy with cataract were operated with VisThesia as an OVD, 1 full ampoule of VisThesia Topical was applied over the corneal surface. The intracameral product was used as a routine OVD during the phacoemulsification procedure. The endothelium of the central cornea was examined preoperatively and 3 months after surgery using a noncontact endothelium microscope. values were comparable with results obtained in other investigations published in the literature using different types of OVDs.

Results

The results observed in this investigation indicate that the addition of lidocaine to the sodium hyaluronate in VisThesia does not induce additional toxicity or increase endothelial cell loss when compared with other, similar OVDs.